Intellia culls 27% of staff as it takes ax to pipeline
4 days ago · Intellia is culling of its staffers as it tosses out pipeline assets to keep ... This is not how Intellia would have wanted to kick off its J.P. Morgan Healthcare Conference news cycle. The CRISPR ...
Intellia slashes workforce by 27% to focus on late stage CRISPR …
1 day ago · CRISPR biotech Intellia Therapeutics has announced plans to reduce its workforce by 27% and halt early-stage R&D programmes as it concentrates resources on two late-stage drug candidates. Intellia ...
Intellia to stop work on rare disease therapy, lay off staff
4 days ago · Dive Brief: Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than one-quarter of its staff in a restructuring meant to prioritize resources around its two most advanced experimental medicines.; The discontinued program, dubbed NTLA-3001, targets a rare lung disease known as alpha-1 antitrypsin deficiency.
Intellia cuts 27% of workforce as it eyes commercial launch
4 days ago · Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development biotech to a commercial-ready company by the end of 2026.
Readout Newsletter: Intellia, Pfizer, Bristol, Eli Lilly latest - STAT
4 days ago · In the meantime, we have news: Gene-editing biotech Intellia cut its workforce by 27%, there’s a unique fund rolling out from Eli Lilly and Andreessen Horowitz, and we report on a new heart ...
Press Releases - Intellia Therapeutics
Dec 3, 2024 · CAMBRIDGE, Mass , Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2025 , it awarded inducement grants to three new employees
Intellia Therapeutics announces net workforce reduction of 27
4 days ago · Intellia Therapeutics announced a strategic reorganization focused on key value drivers.The pipeline prioritization is intended to focus resources on high value programs – NTLA-2002 and nex-z ...
Intellia trumpets CRISPR drug data, but shares fall
4 days ago · Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its...
Intellia Therapeutics Announces Anticipated 2025 Milestones and ...
5 days ago · About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies.
Intellia Therapeutics, Inc. (NTLA) Latest Stock News & Headlines ...
Get the latest Intellia Therapeutics, Inc. (NTLA) stock news and headlines to help you in your trading and investing decisions.
- Some results have been removed